CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($) $ in Millions	Jun. 30, 2025	Dec. 31, 2024
Current assets
Cash and cash equivalents	$ 3,272.8	$ 3,045.2
Short-term investments (Note 5)	789.4	930.7
Accounts receivable, net of allowances of $12.7 and $11.6, respectively	697.0	609.1
Other receivables	205.6	118.3
Inventories (Note 2)	1,141.7	1,086.7
Prepaid expenses	110.0	121.0
Other current assets	314.4	347.6
Current assets of discontinued operations (Note 4)	46.3	26.8
Total current assets	6,577.2	6,285.4
Long-term investments (Note 5)	298.5	307.9
Property, plant, and equipment, net	1,726.6	1,686.0
Operating lease right-of-use assets	99.0	98.2
Goodwill	1,776.7	1,776.7
Other intangible assets, net	1,172.8	1,176.6
Deferred income taxes	1,082.1	992.1
Other assets (Note 2)	743.0	721.6
Non-current assets of discontinued operations (Note 4)	12.8	10.8
Total assets	13,488.7	13,055.3
Current liabilities
Accounts payable	162.1	197.4
Accrued and other liabilities (Note 2)	1,214.4	1,282.4
Operating lease liabilities	25.9	23.4
Current liabilities of discontinued operations (Note 4)	2.3	2.0
Total current liabilities	1,404.7	1,505.2
Long-term debt	598.0	597.7
Operating lease liabilities	78.7	78.9
Uncertain tax positions	421.6	384.6
Other liabilities	379.2	426.0
Total liabilities	2,882.2	2,992.4
Commitments and contingencies (Note 11)
Stockholders' equity
Preferred stock, $0.01 par value, authorized 50.0 shares, no shares outstanding	0.0	0.0
Common stock, $1.00 par value, 1,050.0 shares authorized, 657.6 and 654.8 shares issued, and 587.9 and 588.6 shares outstanding, respectively	657.6	654.8
Additional paid-in capital	2,750.0	2,613.4
Retained earnings	13,858.2	13,167.0
Accumulated other comprehensive loss (Note 12)	(264.1)	(244.5)
Treasury stock, at cost, 69.7 and 66.2 shares, respectively	(6,456.4)	(6,192.3)
Total Edwards Lifesciences Corporation stockholders' equity	10,545.3	9,998.4
Noncontrolling interest	61.2	64.5
Total stockholders' equity	10,606.5	10,062.9
Total liabilities and equity	$ 13,488.7	$ 13,055.3